THE "I"s HAVE IT: IMMUNEX, ISIS EARLY CLINICAL RESULTS WIN FAVOR ON WALL STREET
Immunex' Phase I results for interleukin-4 receptor and FLT-3 ligand helped drive the stock up more than 40% in February trading to close up 8-1/8 to 28-1/4
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.